Science & Technology
Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44HL170779-01A1
Award Ceiling
$2.8M
Award Floor
$2.8M
Close Date
May 31, 2027
442 days leftTotal Funding
$2.8M
Expected Awards
1
Posted Date
Jun 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R44HL170779-01A1
Description
SBIR Phase Phase II award: "Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients" awarded to Innovative Biotherapies, Inc. in Ann Arbor, Michigan. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,827,948. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.